Home Equities Score Annovis Bio, Inc. (ANVS) Stock Skyrockets Following Success of Clinical Trial and...

Annovis Bio, Inc. (ANVS) Stock Skyrockets Following Success of Clinical Trial and Subsequent Public Offering

Annovis Bio, Inc. (ANVS) stock prices skyrocketed by a staggering 127.27% as of the market closing on May 21st, 2021, bringing the price per share up to an even USD$60.00.

Get the hottest stocks to trade every day before the market opens 100% ‎free. Click here now. 

ANVS401 Study

The company announced on May 21st, 2021 the success of its double-blind placebo-controlled study in the treatment of Alzheimer’s Disease. Patients treated with ANVS401 for a period of 25 days exhibited statistically significant cognitive improvement, according to the study. The cognitive improvement was measured by the Alzheimer’s Disease Assessment Scale-Cognitive Subscale 11.


3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free

Sponsored


Read More

Success of Study

The 11-part test is the standard in the measurement of impaired cognition in clinical trials for Alzheimer’s Diseases. The cohort that received ANVS401 showed a statistically significant and highly promising 30% improvement. The same cohort exhibited an improvement of 22% compared with the placebo group.

Pristine Safety Data

Prior safety data had established the safety profile of the ANVS401 drug, with interim analysis reports further consolidating the treatment as safe. The interim analysis showed ANVS401 to be safe at a dosage level and frequency of 80mg once a day in humans, with no adverse events that could have been ascribed to the drug treatment.

Trajectory of ANVS401

Following this success, ANVS expects full study data by the end of the Summer of 2021, including a dose range analysis in a cohort of 40 Parkinson’s patients. After the forecasted success of the Phase 2a trial, ANVS hopes to request a meeting with the U.S. FDA wherein the company will present the results of the trial and its chronic toxicology study in animals. Assuming the company’s trajectory stays on track, it forecasts progression into late-stage studies by later in the fiscal year 2021.

Scope of ANVS401

The company had previously reported positive results in a study involving Parkinson’s disease patients, with ANVS401 proving to be effective in the treatment of both diseases. The study that achieved these results had a cohort of 14 patients with Alzheimer’s Diseases and Parkinson’s Disease each. The efficacy observed in both patient cohorts supports ANVS’s hypothesis that the impairment of axonal transport affects nerve cells in the same way in both diseases. With more than 6 million Americans living with Alzheimer’s, the number is projected to surge to 13 million by 2050.

ANVS Public Offering

May 23rd saw the company announce the pricing of its previously disclosed public offering of shares of its common stock. ANVS will offer up to 1 million shares with a price of USD$50.00 per share. The offering is expected to close on May 26th, 2021, with gross proceeds in the amount of USD$50 million being generated before the deduction of costs related to the offering. The company hopes to use the generated funds to facilitate the completion of the planned Phase 3 clinical trial for ANVS401.

Get the hottest stocks to trade every day before the market opens 100% ‎free. Click here now. 

Future Outlook for ANVS

With such resounding success and a broadened scope for ANVS401, ANVS is poised to capitalize on developments in the commercialization of the treatment. Soon to be armed with a solid liquidity position owing to their ongoing public offering, the company expects to reward its investors with significant and sustained increases in shareholder value.

Get The Best Stocks To Trade Every Day!

Join now to get the NewsHeater.com pre-market morning brief 100% free

Must Read

IT Tech Packaging Inc. (ITP) stock gains during pre-market. Here’s what’s happening?

IT Tech Packaging Inc. (NASDAQ: ITP) stock gained by 7.53% at last close while the ITP stock price rises by 2.04% in the pre-market...

Why did The9 Limited (NCTY) stock turnaround in the after-hours on Friday?

The9 Limited (NCTY) shares gained 6.87% in after-hours on Friday, July 30, 2021, and closed the weekly trading at $11.98 per share. in the...

Energous Corporation Inc. (WATT) stock declines during after-market. Here’s to know why?

Energous Corporation Inc. (WATT) stock gained by 7.05% at last close whereas the WATT stock price plunged by 7.82% in the after-hours trading session....

AMAZON Inc. (AMZN) stock fell during after-market. Here’s the update

Amazon Inc. (NASDAQ: AMZN) stock plunged by 0.84% at last close however moving ahead the AMZAN share price also declines by 7.44% in the...

Cocrystal Pharma Inc. (COCP) stock soars during current market. Here’s what you should know

Cocrystal Pharma Inc. (NASDAQ: COCP) stock gains by 17.44% in the current market trading session. Cocrystal Pharma, Inc. is a clinical-stage biotechnology firm focused...

Best Inc. (BEST) stock gains during current market. Here’s the update?

Best Inc. (NASDAQ: BEST) stock rises by 5.45% during the current market. BEST Inc. is a prominent Chinese supplier of comprehensive smart supply chain...

Dolphin Entertainment Inc. (DLPN) stock rises during current market. Let’s find out why?

Dolphin Entertainment Inc. (NASDAQ: DLPN) stock gains by 17.47% to $9.21 today in the current market trading. Dolphin Entertainment is a leading independent entertainment...

General Electric Company Inc. (GE) stock sky-rocketing during pre-market. Here’s what you should know

General Electric Company Inc. (NASDAQ: GE) stock plunged by 2.56% at last close whereas the GE stock price surged massively during pre-market by 704.32%....

Related News

Best Inc. (BEST) stock gains during current market. Here’s the update?

Best Inc. (NASDAQ: BEST) stock rises by 5.45% during the current market. BEST Inc. is a prominent Chinese supplier of comprehensive smart supply chain...

Dolphin Entertainment Inc. (DLPN) stock rises during current market. Let’s find out why?

Dolphin Entertainment Inc. (NASDAQ: DLPN) stock gains by 17.47% to $9.21 today in the current market trading. Dolphin Entertainment is a leading independent entertainment...

CbdMD Inc. (YCBD) stock gains during after-market, given no recent update

CbdMD Inc. (NASDAQ: YCBD) stock soars by 5.43% in the after-hours trading session. CbdMD, Inc. is one of the most well-known and reputable cannabidiol...

UXIN stock declines during current market trading. What’s driving it low?

Uxin Ltd. (NASDAQ: UXIN) stock declines by 3.41% during current market trading. In China, Uxin Limited is a prominent online used vehicle dealer with...

Synthetic Biologics Inc. (SYN) stock plunged during pre-market. Here’s what you should know?

Synthetic Biologics Inc. (NASDAQ: SYN) stock gained by 8.09% at last close whereas the SYN stock price declines by 0.54% in the pre-market trading....

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Get The Best Stocks To Trade Every Day!

Join now to get the NewsHeater.com pre-market morning brief 100% free

SPECIAL GIFT

WE HAVE A GIFT FOR YOU

Download Free eBook For

7 GROWTH STOCKS FOR 2021

100% free. stop anytime no spam